Cases that are not expedited are still reported, in periodic reports.
US, 21 CFR 314.80(c)(2). Each adverse drug experience not sent as a 15-day Alert report is reported:
- quarterly for the first 3 years after approval, each report within 30 days of the close of the quarter (the first quarter starts on the approval date);
- then annually, each report within 60 days of the anniversary of approval.
The FDA can extend or restore quarterly reporting, for example after a major supplement. A periodic report includes a narrative summary and analysis, the reports not sent as 15-day reports, and a history of actions taken since the last report.
One exception: periodic reporting does not apply to adverse drug experiences from postmarketing studies, from the scientific literature or from foreign marketing experience; those reach the FDA only as 15-day Alert reports (314.80(c)(2)(iii)).
ICH E2C(R2). The periodic benefit-risk evaluation report (PBRER) looks at the product's whole benefit-risk balance over a reporting interval, not only at single cases. In the EU this is the format of the periodic safety update report (PSUR).